Related references
Note: Only part of the references are listed.Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Esben Andreas Carlsen et al.
ENDOCRINE-RELATED CANCER (2019)
Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
Rebekka Mai et al.
SCIENTIFIC REPORTS (2019)
Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis
Massimo Milione et al.
ENDOCRINE-RELATED CANCER (2018)
The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond
Halfdan Sorbye et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study
Guido Rindi et al.
NEUROENDOCRINOLOGY (2018)
The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors
Philippe Brunner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione et al.
NEUROENDOCRINOLOGY (2017)
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T. Walter et al.
EUROPEAN JOURNAL OF CANCER (2017)
Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%
Bjoern Konukiewitz et al.
MODERN PATHOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification
Aurel Perren et al.
NEUROENDOCRINOLOGY (2017)
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
Abir Salwa Ali et al.
PLOS ONE (2017)
Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
Patricia Freis et al.
SCIENTIFIC REPORTS (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review
Daniel M. Girardi et al.
CANCER TREATMENT REVIEWS (2017)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications
Nicola Fazio et al.
CANCER TREATMENT REVIEWS (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
Martin Kobel et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J. Hadoux et al.
ENDOCRINE-RELATED CANCER (2015)
Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
Shreya Mehta et al.
MEDICINE (2015)
P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters
Elife Kimiloglu Sahan et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2015)
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
Daniel Kaemmerer et al.
ONCOTARGET (2015)
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
Emma Elizabeth Ilett et al.
DIAGNOSTICS (2015)
Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
Yu-hong Wang et al.
MEDICINE (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Prognostic Impact of Cyclin D1, Cyclin E and P53 on Gastroenteropancreatic Neuroendocrine Tumours
Shu-Zheng Liu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments
Catharina M. Korse et al.
EUROPEAN JOURNAL OF CANCER (2012)
Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance
W. Glenn McCluggage et al.
HISTOPATHOLOGY (2011)
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Anna Yemelyanova et al.
MODERN PATHOLOGY (2011)
Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
Tina Binderup et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Share Paper
